This page contains real world evidence. This is a real patient with eosinophilic asthma, compensated by GSK for his time.
The right treatment for the right patient

Nucala (mepolizumab) is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older1

This is a fictional patient for demonstration purposes. For severe refractory eosinophilic asthma, the recommended dose of Nucala is 100mg SC once every 4 weeks in adults and adolescents 12 years and older. The licensed dose of Nucala in children aged 6-11 years is 40mg SC once every 4 weeks regardless of weight.1

Are your patients eligible for Nucala?

Nice Guidance

*All Wales Medicines Strategy Group refer to the NICE technology appraisal for mepolizumab, therefore adopt the criteria set out in the NICE guidance.4

SMC Guidance

The right treatment for the right patient

Find out more below about the types of patients who could benefit from Nucala.

42 years old

"I just came off the prednisolone - I'm concerned about the weight gain and the longer term risk of osteoporosis."

  • Asthma diagnosis 15 years ago
  • 4 exacerbations in the past year
  • 3 courses of oral steroids in the past year
  • Eosinophil count: 300 cells/μL
  • Total IgE: 118kU/L
  • High dose ICS/LABA + LAMA
  • FEV1 % predicted: 66%

 

Nucala Identifying Patient

Fictional patient profile for illustrative purposes.

Find out how Nucala could help to reduce or eliminate OCS use for your patients

40 years old

''I don't want to be a burden to others but I know I am at risk life-threatening asthma attacks''

  • Asthma diagnosis 22 years ago
  • 4 exacerbations in the past year (including 2 hospitalisations)
  • Eosinophil count: 463 cells/μL
  • Total IgE: 352kU/L
  • 4 bursts of oral steroids in the past year
  • FEV1 % predicted: 55%
  • High-dose maintenance ICS/LABA,

 

Nucala Identifying Patient

Fictional patient profile for illustrative purposes.

Explore how Nucala could enable patients to have fewer exacerbations

35 years old

''It feels like I can't get a break from my asthma symptoms and the nasal polyps make me feel even worse. It is really difficult to breathe, especially through my nose''.

  • Asthma diagnosis 20 years ago
  • 4 exacerbations in the past year
  • Eosinophil count: 424 cells/μL
  • Total IgE: 315kU/L
  • FEV1 % predicted: 66%
  • High dose ICS/LABA, SABA as needed
Nucala Identifying Patient

Fictional patient profile for illustrative purposes.

Explore how Nucala help to reduce exacerbations in your patients with severe eosinophilic asthma and comorbid nasal polyps.

Footnotes

ED, emergency department; ICS, inhaled corticosteroid; IgE, immunoglobulin E; LABA, long acting beta agonist; LAMA, long acting muscarinic antagonist NICE, The National Institute for Health and Care Excellence; OCS, oral corticosteroid; SABA, short acting beta agonist; SC, subcutaneous; SMC, Scottish Medicine Consortium.

References

  1. Nucala SmPC
  2. National Institute for Health and Care Excellence (NICE) - Technology Appraisal Guidance Mepolizumab [TA671; 3 Feb 2021]. Accessed via: https://www.nice.org.uk/guidance/ta671/resources/mepolizumab-for-treating-severe-eosinophilic-asthma-pdf-82609314548677. Last accessed November 2022.
  3. Commissioning Medicines for Children in Specialised Services. NHS England: 170001/P. Last updated: March 2017. Accessed via: https://www.england.nhs.uk/publication/commissioning-medicines-for-children-specialised-services/. Last accessed November 2022.
  4. All Wales Medicines Strategy Group Medicines appraisals and guidance for mepolizumab (0619 April 2019). Accessed via: https://awttc.nhs.wales/accessing-medicines/medicine-recommendations/mepolizumab-nucala/. Last accessed November 2022.
  5. SMC - Scottish Medicines Consortium (SMC2139 April 2019). Accessed via: https://www.scottishmedicines.org.uk/medicines-advice/mepolizumab-nucala-abbreviated-smc2139/. Last accessed November 2022.

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441

© 2021 GSK group of companies or its licensor.
Trademarks are owned by or licensed to the GSK group of companies.

November 2022 | PM-GB-MPL-WCNT-200027 (V6.0)